Interventional cardiologists at The Mount Sinai Hospital in October became the first in the world to use a new device to remove hard calcium buildup in a coronary artery in preparation for the placement of a stent to improve blood flow through the artery. The device, the Diamondback 360® Coronary Orbital Atherectomy System, was approved by the U.S. Food and Drug Administration one day before it was brought to Mount Sinai for use.
Since then, Mount Sinai’s cardiac catheterization team has performed more than 25 procedures under the leadership of Samin K. Sharma, MD, Director of Clinical and Interventional Cardiology at The Mount Sinai Hospital. Dr. Sharma says there have been no complications during or after the procedures.
Amid festive red and white balloons, and samples of heart-healthy and tasty pasta dishes, salads, and desserts, more than 500 individuals from Mount Sinai and the community attended a Mount Sinai health fair in Guggenheim Pavilion on Friday, February 1. The event was part of the American Heart Association’s annual Go Red for Women® campaign that educates women about cardiovascular risks.
A special feature of this year’s health fair was the launch of H.A.P.P.Y. (Heart Attack Prevention Program for You), a cardiovascular screening and follow-up consultation program for all Mount Sinai employees that will continue to be offered over the coming months by Mount Sinai’s Cardiac Catheterization Laboratory.
Valentin Fuster, MD, PhD, Director of Mount Sinai Heart, presented landmark research on diabetes and heart disease at the American Heart Association (AHA) Scientific Sessions 2012. During the conference, the AHA also honored Dr. Fuster with its 2012 Research Achievement Award for his many significant contributions to cardiovascular medicine.
“With a laser-like focus on translational research, Dr. Fuster has added greatly to our understanding of the pathogenesis of coronary artery disease and thrombosis,” says AHA President Donna Arnett, PhD, MSPH. “Among his laboratory’s provocative advancements in medical science are numerous ‘firsts,’ including the original understanding of the role of platelets in heart disease and the revelation that plaque composition plays a crucial role in propensity for a heart lesion to rupture.”
When Daquain Jenkins, 29, left The Mount Sinai Hospital last year, he became the first patient in the New York metropolitan area to return home to await a heart transplant with the assistance of a portable artificial heart.
The milestone was remarkable in a number of ways. First, the Total Artificial Heart, manufactured by SynCardia Systems, Inc., in Tucson, Arizona, replaces both failing heart ventricles and four heart valves, eliminating end-stage biventricular failure. It is immediately available to patients, and serves as a bridge while they await a suitable heart donor. In addition, it allows patients to move freely and manage everyday chores while wearing a backpack that stores the 13.5-pound battery-driven device.